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Abstract
Long standing, evidence based approved therapies for acute ischemic stroke include intravenous thrombolysis
therapy (IVT) with alteplase (recombinant tissue plasminogen activator, rtPA) given within 4.5 h; aspirin therapy
within 48 h; management in an acute stroke unit and hemicraniectomy in cases of malignant infarction. Multiple
recent positive randomized controlled trials (RCTs) have now also established endovascular therapy with
mechanical thrombectomy as the standard of care for acute ischemic stroke involving a large vessel
occlusion in the anterior circulation.
This article will review the history of endovascular treatments for acute ischemic stroke and will review
the recent positive and negative randomized controlled trial evidence for its efficacy. Current guidelines
and dilemmas regarding appropriate patient selection will be discussed.
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Background
IVT is the standard of care for acute ischemic stroke
[1–3]. Yet IVT must be delivered rapidly within
4.5 h, and has many contraindications. Furthermore,
many patients with large or proximal clots may not
achieve adequate reperfusion with thrombolysis, and
treatment carries the risk of intracranial haemorrhage,
which can be fatal.
As a result, there have been a wide variety of dedi-
cated trials over the past 20 years to treat proximal
clots not responsive to thrombolysis with interven-
tional and mechanical means. As reviewed below,
early trials in endovascular therapy did not demon-
strate a benefit in patients with acute ischemic stroke,
whereas newer trials have demonstrated substantial
efficacy in the treatment of proximal occlusions pro-
ducing a major breakthrough for treatment options in
hyperacute ischemic stroke.
Early experience with endovascular treatment in acute
stroke
Intra-arterial thrombolysis (IAT)
The PROACT trials introduced the initial promise of
intra-arterial treatment for ischemic stroke [4, 5].
PROACT I demonstrated IAT administration of 6 mg
pro-urokinase in patients with M1 or M2 occlusions
resulted in higher recanalization rates, although all
patients received intravenous heparin, and clinical out-
comes were not measured. In PROACT II, patients with
angiographically proven proximal MCA occlusions were
randomized to receive IAT with 9 mg of pro-urokinase
(given proximal to the clot and mechanical clot disrup-
tion with the guide wire was not allowed) plus heparin
or heparin only in the control arm. Pro-urokinase ad-
ministration within 6 h resulted in a significantly higher
number of patients with modified Rankin scale (mRS)
score of 2 or less at 90 days (40% v 25%), with recanali-
zation rates of 66% v 18%. Symptomatic intracranial
haemorrhage occurred in 10% versus 2% in controls and
mortality was 25% versus 27% in controls. Pro-urokinase
was never approved by the FDA for this indication,
citing the need for a confirmatory trial that was never
performed.
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First generation thrombectomy devices
Following the results of the 1999 PROACT II trial, the
MERCI retriever device was developed. This was the
first generation of mechanical thrombectomy devices
approved by the FDA, and propelled an era of interven-
tional stroke trials. MERCI devices were found to
achieve recanalization rates (defined as thrombolysis in
myocardial infarction score (TIMI) 2 or 3 flow in in-
ternal carotid artery (ICA), M1 and M2 (first and second
portion of the middle cerebral artery (MCA) branches)
of 46% in the first MERCI trial and 55% in the follow up
MULTI MERCI trial [6, 7]. Good clinical outcome
(modified Ranking Scale, mRS ≤ 2) was 28 and 36% in
the two trials but mortality remained high (44 and 34%
respectively). However both trials, which treated patients
within 8 h, were single arms trials compared to historical
controls. Nevertheless, patients with successful recanali-
zation were more likely to achieve good clinical
outcome, establishing a clinical rationale for early recan-
alization after acute stroke.
Second generation thrombectomy devices
The results of a second generation device, the Penumbra
aspiration system, were reported in the Penumbra Piv-
otal Stroke Trial [8]. This trial was not randomized but
rather the goal of the trial was to provide substantial
equivalence in safety and effectiveness to the MERCI
device in opening occluded blood vessels in stroke. High
vessel revascularization rates (defined as TIMI 2 or 3
flow at the site of primary occlusion only) of 82% were
achieved compared to those reported for the MERCI
device. However clinical outcomes remained poor with
only 25% achieving a good clinical outcome (mRS ≤ 2)
and high all-cause mortality rate of 33%. Complication
rates were high with 12.8% of patients experiencing a
procedural complication, of which 2.4% were considered
serious, and a 24 h intracranial haemorrhage (ICH) rate
of 28% with a symptomatic ICH rate of 11.2%. Similar to
the MERCI trials, an 8 h time window was used.
Third generation thrombectomy devices
The SOLITAIRE and Trevo devices were both retriev-
able stents, a technology that continued the evolution of
thrombectomy device. Promising recanalization rates
and clinical outcomes, as compared to the Merci device,
were reported in the SWIFT and TREVO 2 trials,
heralding what was to come in later RCTs [9, 10].
2013 – the year of three negative EVT RCTs (Tables 1, 2, 3 and 4)
In March 2013, three randomized controlled trials, SYN-
THESIS, MR RESCUE, and IMS III, were presented at
the International Stroke Conference in Hawaii and sub-
sequently published in the same issue of the New
England Journal of Medicine. Very disappointingly all
three trials reported negative results [11–13].
Using the MERCI retriever or PENUMBRA system,
MR RESCUE, completed over an 8 year period, com-
pared patients receiving endovascular therapy versus
those receiving standard care. Inclusion criteria included
demonstration of intracranial ICA or M1 occlusion,
NIHSS greater or equal to 6 and once again the eligible
time window was within 8 h. Forty-four percent received
tPA in the endovascular arm compared to 30% in the
standard care arm. There was no outcome difference be-
tween groups, irrespective of whether the patient had a
favourable penumbral pattern or nonpenumbral pattern
based on perfusion imaging. Reperfusion, defined as
modified thrombolysis in cerebral infarction score
(mTICI) 2a/3 was 67% and defined as mTICI 2b/3 was
only 27%. Good clinical outcome (mRS 0–2) was only
demonstrated in 14%. Older generation devices were
used and the mean time to endovascular procedure was
6 h and 21 min.
IMS III was a large, randomized controlled trial com-
paring endovascular therapy plus IVT (IVT stopped at
40 min) to IVT alone. Demonstration of intracranial oc-
clusion was not required. In IMS III, National Institutes
of Health Stroke Scale, NIHSS ≥10 was used as a marker
of stroke severity and risk of proximal occlusion, but as
Computed Tomography Angiography, CTA became
more widespread, an amendment mid-way through the
trial allowed screening for proximal clots with CTA for
patients with NIHSS of 8 or 9. MERCI, PENUMBRA,
SOLITAIRE, or Microcatheter delivery of intra-arterial
tPA was allowed. As a result, the methods were a mix of
pharmacological thrombolysis, manipulation of clot with
use of a guidewire or microcatheter, mechanical and
aspiration thrombectomy, and stent-retriever technology.
The procedure was required to begin within 5 h. Disap-
pointingly, there was no difference in outcome between
groups with 41% good clinical outcome (mRS 0–2) in the
combined IVT/EVT arm versus 39% in the IVT only
arm. Recanalization rate (defined as modified arterial
occlusion lesion score mAOL 2–3) was 81% for ICA
occlusion and 86% for M1 occlusion; the reperfusion rate
(mTICI 2b/3) was 38% for ICA occlusion and 44% for M1
occlusion. Retrievable stents were only used in 14 patients.
The SYNTHESIS trial compared endovascular therapy
(intra-arterial thrombolysis with rtPA, mechanical clot
disruption or retrieval or a combination of these
approaches) to treatment with intravenous tPA alone.
Demonstration of vessel occlusion prior to endovascular
treatment was not required nor was any clinical severity
rating on the NIHSS. Reperfusion rates were not
reported. There was no difference in good clinical out-
come −42% in the endovascular arm versus 46% in the
intravenous tPA arm. A mechanical device was only
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used in 56/181 patients randomized to endovascular
treatment; however, this trial did see the introduction of
the third generation of mechanical devices, the retriev-
able stents, which were used in 23/56 patients in whom
a device was deployed.
Overall, these three trials failed to show a benefit for
endovascular intervention in ischemic stroke. However, a
variety of limitations were identified and addressed in the
design of new endovascular therapy RCTs [14, 15]. Firstly,
the use of non-invasive angiography was not universal in
patient selection. For example, in IMS III, more than 50%
of patients did not undergo CTA, as it was not in wide-
spread use during early patient recruitment. In MR RES-
CUE, patients were eligible only if angiography showed
persistent target occlusion after receiving tPA. Secondly,
there were long time delays from stroke onset to
Table 2 Baseline characteristics
Age (median) Male (%) NIHSS
(median)
Vessel occlusion Tandem lesion
(extrancranial
ICA occlusion)
ASPECTS (median) IVT (%) Retrievable
stent (%)
MR RESCUE 66 50 16 71% ICA or M1* nr predicted core
36 ml*
47* 0
IMS III 69 50 17 18% of EVT group
had no occlusion
nr nr 100 4
SYNTHESIS 66 59 13 2% no occlusion nr nr 0 41
PISTE 67 39 18 90% carotid T/L
or M1
3% 9 100 68
THERAPY 67 62 17 89% I-ICA or M1 excluded 7.5 100 13% (majority
used aspiration
thrombectomy)
MR CLEAN 66 58 17 92% I-ICA, carotid
T or M1
32% 9 87
(44% drip & ship)
82
ESCAPE 71 48 (87%
white)
16 96% carotid T/L
or M1
13% 9 73 73
EXTEND_IA 69 49 17 88% I-ICA or M1 n/r n/r
(median core 12 ml)
100 100
SWIFT PRIME 65 55 (89%
white)
17 86% carotid T/L
or M1
excluded 9 100
(44% drip & ship)
100
REVASCAT 65 55 17 90% carotid T/L
or M1
19 7 70 70
THRACE 66 57 18 98% ICA or M1 excldued nr 100
(100% mothership)
77
aMR RESCUE values reported for penumbral group receiving embolectomy























MR RESCUE nr nr 381 nr nr nr 124 nr
IMS III 122 nr 208 nr nr nr nr nr
SYNTHESIS 165 148 225 nr nr nr nr nr
PISTE 120 150 209 259 49* 82 58# nr
THERAPY 108 181 227 nr nr nr 123 nr
MR CLEAN 85 204 260 332 nr nr nr nr
ESCAPE 110 169 208 241 30 51 51 84
EXTEND_IA 127 156 210 248 43 74 93 nr
SWIFT PRIME 111 191 224 252 nr nr 58 87
REVASCAT 118 223 269 355 59 nr 67 nr
THRACE 150 168 250 nr nr nr nr nr
aGroin puncture to device removal
bRandomisation to groin puncture
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revascularization, in part due to lack of rapid workflow.
Lastly, devices were relatively limited in their ability to
achieve recanalization and the new generation retrievable
stents were used in a small number of patients.
Recent landmark positive RCTs demonstrating efficacy
and safety of EVT (Tables 1, 2, 3 and 4)
In 2015 the landscape completely changed with the pub-
lication of five randomized controlled trials showing
positive results for endovascular treatment in patients
with acute ischemic stroke. presenting with large vessel
occlusion in the anterior circulation [16–20]. A sixth
positive trial has been published in 2016 [21]. These six
trials focused on the previous deficiencies in order to
maximize work-flow and patient selection, by 1) man-
dating universal vascular imaging to identify patients
with proximal occlusion 2) emphasizing rapid door-to-
recanalization times, and 3) use of advanced retrievable
stent technology.
The first landmark positive trial was MR CLEAN, pre-
sented at the 9th World Stroke Congress in October
2014. The trial recruited patients within 6 h of onset,
with proximal occlusion of the anterior circulation (dis-
tal ICA, M1 or M2, first or second portion of Anterior
cerebral artery, A1 or A2), and NIHSS >2. This was a
very pragmatic trial conducted within a single country
(the Netherlands) and it is important to note that nei-
ther the basic non contrast Computed Tomography,
NCCT brain Alberta Stroke Program Early CT Score, (-
ASPECTS score) nor advanced clinical imaging (collat-
eral scoring or perfusion imaging) were used to identify
and exclude patients with large core infarction. The vast
majority of patients received IVT (89%) and 82% of
patients were treated with retrievable stents. This trial
shifted from using a dichotomized mRS as the primary
outcome to using the adjusted common odds ratio for a
shift in the direction of a better outcome on the mRS.
The adjusted common odds ratio was 1.67 (95% CI 1.21
to 2.30), representing the first positive RCT for endovas-
cular therapy. Statistically significantly more patients
achieved functional independence (mRS 0 to 2) at
90 days in the intervention group, 33% compared to 19%
(95% CI 5.9 to 21.2) with an adjusted odds ratio of 2.16
(95% CI 1.39 to 3.38).
Following early interim analyses prompted by these
positive results, five other ongoing RCTs stopped re-
cruitment early and swiftly produced concordant results.
MR CLEAN therefore remains the only fully powered
study. Unpowered studies may overestimate effect size
but it is reassuring that the same positive result was ob-
tained in five different prematurely terminated RCTs.
Those trials will now be discussed.
The ESCAPE trial, conducted February 2013 to
October 2014 across 22 sites in Canada, United States,
Ireland and South Korea, allowed recruitment of
patients within 12 h, the longest time window of all the
trials, with clinical severity requirements for inclusion
set at a NIHSS >6. Additional advanced imaging criteria
were also required: (i) NCCT ASPECTS >5 aimed at
identifying small core infarcts; (ii) proximal intracranial
occlusion of M1, M2, or intracranial ICA was required
on vascular imaging, with tandem occlusion of the
extra-cranial internal carotid artery also allowed; and
(iii) moderate to good collaterals, defined as filling of
>50% of MCA pial arterial circulation on CTA, prefera-
bly acquired with multiphase CTA. Although not obliga-
tory, if CT perfusion was used, a low CBV or very low
CBF ASPECTS >5 was needed. This trial also mandated
an imaging-to-groin puncture time of <60 min and a tar-
get groin puncture to reperfusion time of < 30 min.
Wake up strokes and patients ineligible for intravenous
tPA were also accepted if the above criteria were ful-
filled. Rapid workflow was emphasized, thus achieving
the shortest onset-to-reperfusion time among the
trials - the median stroke onset to reperfusion was
4 h. Seventy-six percent of patients received IVT. The
trial demonstrated an increase in functional independ-
ence (mRS 0–2) at 90 days from 29% in the control
group to 53% in the intervention group (p < 0.001)
and the primary outcome favoured the intervention
with a common odds ratio of 2.6 (95% CI 1.7 to 3.8;
p < 0.001). ESCAPE was the only trial to demonstrate
a statistically significant reduction in mortality from
19 to 10% (p = 0.04).
The Australian and New Zealand EXTEND-IA trial,
conducted from August 2012 through October 2014
across ten sites, had the most stringent selection criteria
and was the only one to mandate perfusion imaging, re-
quiring evidence of salvageable tissue using the auto-
mated RAPID software (ischemic core of less than
70 mL and target mismatch of >1.2 on perfusion im-
aging). This was also the only trial to report a screening
log - 7798 patients were screened, with 1044 (7%) receiv-
ing IVT and 70 (1%) receiving endovascular therapy.
Four hundred ninety-five of 1044 (47%) of patients
treated with IVT were excluded because CTA did not
demonstrate a large artery occlusion. It was estimated
that 25% of clinically eligible patients for thrombectomy
were excluded on the basis of perfusion imaging alone.
All randomized patients received IVT and endovascular
treatment commenced within 6 h. This highly selected
cohort translated into excellent outcomes – the reperfusion
rate was impressive (mTICI 2b/3 86%) and this trial had
the largest effect size, with 71% of patients in the interven-
tion group achieving functional independence (mRS 0–2)
at 90 days, compared to 40% in the control arm (p = 0.01,
relative risk, RR 1.8). Furthermore, this trial demonstrated a
large trend to mortality benefit (20 to 9%), although unlike
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the ESCAPE trial the difference was not statistically signifi-
cant (RR 0.4, 95% CI 0.1–1.5), probably due to the small
sample size.
In SWIFT-PRIME, conducted in 39 United States and
European sites between December 2012 to November
2014, the initial premise was to select a target-mismatch
penumbra profile (core <50 ml, ischemic tissue with
time to the peak of the residual function, Tmax >10 s
<100 ml, mismatch volume >15 ml and mismatch ratio
>1.8) using the automated RAPID penumbral imaging
software. However, perfusion mismatch was a require-
ment in only 71 patients before the protocol was chan-
ged to one identifying small core infarcts (NCCT
ASPECTS >5) in the next 125 patients. All patients
received IVT and the endovascular procedure had to
start within 6 h. This trial had the highest rate of reper-
fusion (mTICI 2b/3 88%) and demonstrated improve-
ment in functional independence (mRS 0–2) at 90 days
with 60% in the intervention group versus 36% in con-
trols (RR 1.7, 95% CI 1.23–2.33, p < 0.001).
REVASCAT was the last of the five key studies pub-
lished in 2015 and randomized patients from Nov 2012
to December 2014 from four centres in Catalonia, Spain.
A longer time window was allowed (endovascular pro-
cedure to start within 8 h of stroke onset) and patients
were recruited either due to contraindication to IVT
(32%), or lack of revascularization 30 min after tPA infu-
sion. The trial was stopped after the first planned in-
terim analysis when only 25% of patients had completed
90 days of follow-up. Although the pre-specified bound-
aries for stopping were not met the steering committee
elected to stop the trial due to lack of equipoise follow-
ing the results of the other positive RCTs. REVASCAT
included patients with an NIHSS ≥6 with proven vessel
occlusion of the intracranial ICA, MCA or M1 trunk;
tandem proximal ICA/MCA-M1 occlusions were
allowed. This trial used the highest cut-off on ASPECTS
score for inclusion (ASPECTS >6) but also demonstrated
the challenges around using this score to exclude
patients – the core lab would have excluded 25% of
participants with ASPECTS ≤ 6 and a further 9% who
had occlusion of a single M2 only. REVASCAT had the
longest door-to-groin puncture time of 269 min. Never-
theless, there were still positive results: the primary
outcome demonstrated a common odds ratio of im-
provement in the distribution of the mRS score of 1.7
(95% CI 1.05–2.8) and the proportion with good out-
come (mRS 0–2) increasing from 28 to 44% (adjusted
odd ratio 2.1, 96% CI 1.1 to 4.0).
The THRACE (THRombectomie des Artères CEre-
brales) trial was the most recently published RCT
appearing online in August 2016. Patients were recruited
from June 2010 to February 2015 from 26 centres in
France. This trial compared IVT within 4 h (changed
from 3 h after 14 May 2011 and 80 patients enrolled) to
IVT within 4 h plus mechanical thrombectomy starting
within 5 h, the shortest time window of all trials. In-
cluded patients had NIHSS 10–25 and proximal vessel
occlusion. The trial included over 400 patients making it
the second largest thrombectomy trial behind MR
CLEAN (n = 500). THRACE resembled IMS with a bridg-
ing IV/IA protocol but used the newest stent retrievers and
aspiration devices. Importantly imaging assessment of in-
farct/ischemic extent using ASPECTS or perfusion was not
used to exclude patients representing the widest patient se-
lection profile of all RCTs to date. Interestingly, 17/57
(30%) of patients with ASPECTS 0–4 had a good clin-
ical outcome. Unlike the other trials that incorporated
a drip and ship model, THRACE only included pa-
tients presenting directly to an interventional centre,
representing a mothership model of care. This trial
used functional independence (mRS 0–2) at 3 months
as the primary outcome and was also a positive trial,
with a significantly higher proportion in the mechanical
thrombectomy arm reaching this good outcome - 53%
versus 42%, (OR 1.55 95% CI 1.05–2.3; p = 0.028). The
lower difference between intervention and control group
was thought to reflect the longer randomization to groin
puncture time of 82 min which would have adversely
affected the intervention arm. The rate of IA reperfusion
(TICI 2b-3) was 69%.
Not all recent RCTs have been positive
THERAPY, using the Penumbra aspiration system rather
than a retrievable stent, presented in 2015 and pub-
lished in September 2016 and PISTE, a pragmatic trial
conducted in the UK only, have both reported a trend to
improved outcome that did not reach statistical signifi-
cance [22, 23]. In an attempt to identify the poorest
prognosis patients the THERAPY trial targeted patients
with a thrombus length of 8mm or longer but failed to
show any significant difference in the primary outcome
of functional independnece (mRS 0-2) at 90 days, 38%
IAT v 30% IVT groups (p=0.52).
Efficacy and safety
The evidence is overwhelmingly in favour of endovascu-
lar thrombectomy for large vessel occlusion in patients
with acute ischemic stroke. All trials aimed for rapid re-
canalization, mandated advanced imaging, to greater or
lesser degrees, for patient selection, and used newer-
generation retrievable stents. These improvements likely
resulted in positive effect sizes where previous trials
failed. In keeping with this, in a sub-analysis of IMS III,
patients with documented occlusion who achieved re-
canalization within 6 h had a significant benefit [24]. All
trials showed increased functional independence at
90 days with treatment with only one study, ESCAPE,
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showing significantly reduced mortality. Variability in
effect size likely relate to slightly different selection
criteria, devices used, and speed of treatment.
There was no increase in the rate of intracranial haem-
orrhage in any of the trials despite concurrent use of
thrombolysis for the majority of patients. In the MR
CLEAN trial, there was a low rate of distal embolization
into new territories (8.6%), procedure-related dissections
(1.7%), and vessel perforations (0.9%).
Meta-analyses of trials
Multiple meta-analyses, including various combinations of
the three negative RCTs published in 2013 (MR RESCUE,
IMS III and SYNTHESIS) with the six positive RCTs pub-
lished or presented in 2015 (MR CLEAN, ESCAPE,
SWIFT-PRIME, EXTEND IA, REVASCAT, THRACE) have
confirmed the benefit of endovascular thrombectomy in
large vessel occlusion [25–30]. The HERMES collaboration
analysed individual patient level data from five of the six
positive RCTs published in 2015 (MR CLEAN, ESCAPE,
REVASCAT, SWIFT-PRIME and EXTEND-IA; THRACE
had not yet been published) [25]. For the primary outcome
(the degree of disability on the mRS) the adjusted combined
odds ratio for reduced disability at 90 days was 2.49, 95%
CI 1.76–3.53, p < 0.0001. The number needed to treat for
one patient to have reduced disability of at least 1 point on
the mRS was 2.6. The adjusted odds ratio for patients
achieving functional independence (mRS 0–2) at 90 days
was 2.71 (95% CI 2.07–3.55; p < 0.0001).
In another meta-analysis, including the negative 2013
RCTs with the same five positive new trials as HERMES,
the odds ratio summary statistic for reduction of disability
at 90 days was 1.56; 95% CI 1.14–2.13; p = 0.05 and the
odds ratio for functional independence (mRS 0–2) at
90 days was 1.71 (1.18–2.49) [26]. The largest meta-analysis
to date included the above eight trials but also preliminary
data from THERAPY and THRACE, and showed similar
benefit with risk ratio for good functional outcome (mRS
0–2) at 90 days reported as 1.37; 95% CI 1.14–1.64 [27]. A
subgroup of the seven trials published or presented in
2015, more reflective of current practice with improved pa-
tient selection and use of retrievable stents, yielded a risk
ratio of 1.56 (95% CI 1.38–1.75) for a good functional out-
come (mRS 0–2) at 90 days. Consistently, all the various
meta-analyses showed no significant difference in mortality
or intracranial haemorrhage.
Several cost utility and cost effectiveness analyses have
suggested that although EVT is a costly procedure it is
likely to be cost effective [31–33].
Patient selection - Guidelines and controversies
Based on the recent positive RCTs, multiple guidelines
around the world (eg American Heart Association – AHA,
Canadian Stroke Best Practice - CSBP and European Stroke
Organization - ESO) have been developed to synthesize the
patient selection criteria and facilitate decision making
[34–36]. All now recommend endovascular therapy as the
new standard of care for patients with acute ischemic
stroke presenting with a large vessel intracranial occlusion
(i.e., occlusion of the distal internal carotid artery or prox-
imal middle cerebral artery) identified on vascular imaging,
and provide their highest level of recommendation for vari-
ous other clinical and radiological criteria:
(1)neurologic deficits (CSBP – disabling stroke;
AHA - NIHSS ≥ 6; ESO - not defined)
(2)time (CSBP – within 6 h with a level B
recommendation for patients up to 12 h based
on ESCAPE criteria; AHA – 6 h; ESO – 6 h)
(3)lack of an established infarct i.e., a small core,
(CSBP - ASPECTS ≥6; AHA - ASPECTS ≥6;
ESO – Grade B, level 2a for “large infarcts may be
excluded” but no ASPECTS cut-off suggested)
(4)advanced imaging - Intracranial vascular imaging is
strongly recommended for decision making, but the
benefits of additional imaging such as MRI or CT
perfusion are unknown.
(5)baseline function – the AHA guideline is the only
one to explicitly mandate a certain level of baseline
function, i.e., a pre-stroke mRS score 0 to 1
(6)intravenous tPA – all recommend treatment
with IVT for eligible patients prior to endovascular
therapy. However both the CSBP and ESO guidelines
maintain their highest level of recommendation for
patients ineligible for IVT whereas the AHA reduce
their level of recommendation for this subgroup (class
IIa, level C)
(7)type of anesthesia – conscious sedation is preferred
over general anesthesia (unless medically indicated)
by both AHA and CSBP recommendations, albeit
with reduced levels of evidence (class IIb level C and
level B respectively) whereas the ESO guideline
leaves this as an individual patient decision. Several
RCTs are underway to address this issue [37, 38].
(8)age – an upper age limit is not specified by any of
the guidelines with the ESO guideline explicitly
stating that “high age alone is not a reason to
withhold mechanical thrombectomy”, assigning this
recommendation Grade A, level 1a evidence.
(9)Tandem occlusions (additional extracranial ICA
occlusion): both the CSBP and ESO guidelines do
not provide an explicit recommendation for this
cohort. However, the AHA guideline states that
“angioplasty or stenting of proximal cervical
atherosclerotic stenosis or complete occlusion at
the time of thrombectomy may be considered but
its usefulness is unknown” (Class IIb, Level C)
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(10)Type of device – The use of retrievable stents is
recommended with the highest level of evidence
by all three guidelines, with lower levels of
recommendations given to consider other devices
based on local protocols. A recent analysis of the
MR CLEAN data showed that choice of device
did not influence outcomes in that data set. The
majority were treated with the Trevo device, 53%,
Solitaire device 13% and other device 17% [39].
Conclusions
Endovascular therapy is now the standard of care in pa-
tients with large vessel anterior circulation occlusion.
This creates challenges in providing care to appropriate
patients within a rapid timeframe, since only few highly
specialized centres have access to the necessary skills
and technology [40, 41]. Peripheral centres may or may
not have rapid access to non-invasive angiographic im-
aging 24/7 in order to screen stroke patients for large
vessel occlusion. Therefore currently decisions to
transfer patients to tertiary care centre must be made
on the basis of patient presentation and non-contrast
head CT, which can be challenging. Whether it is best
to build the capacity of peripheral centres in providing
vascular imaging (providing more accurate diagnosis by
screening out clinical false positives but delaying arrival
to endovascular centres), or centralizing acute stroke
care by transferring all patients who have a possibility
of large vessel occlusion (rapid access for selected
patients, but many false negatives will place a large
burden on tertiary care centres), must be further
determined.
The expanded and varying time window used across
the trials creates challenges and opportunities in
treating patients with proximal occlusion (Fig. 1).
“Wake up strokes,” typically deemed out of the time
window for thrombolysis given the lack of clear time
of onset, may be candidates for endovascular therapy
if a proximal occlusion is identified (Fig. 2) [42].
Multi-model imaging, including perfusion, and
Fig. 1 Illustrative cases of difficult patients pushing boundaries of conventional therapeutic criteria: Advanced age and baseline function.
Ninety-five year old male with known dementia – lives at home with his wife, ambulates independently but needs assistance with activities of daily
living; pre-stroke mRS 3. Presents with a left MCA syndrome, NIHSS 22. Very early presentation with very favourable imaging – ASPECTS 9 on NCCT (a).
Note the hyperdense right proximal MCA. CTA (b) confirmed a left M1 occlusion with a large clot extending along the M1 trunk into the M2 vessels.
Good collaterals were present with a large mismatch on CT perfusion (c). The patient was treated with IVT - door to needle (DTN) time 32 min; onset
to tPA treatment (OTT) time 74 min. Successful EVT recanalization at 150 min post stroke onset (d). A small deep infarct was present on DWI (e). Patient
was discharged home on day 8 with NIHSS of 5 and was ambulating independently
Fig. 2 Illustrative cases of difficult patients pushing boundaries of conventional therapeutic criteria: Unclear time of onset. Twenty-nine year
old male last seen normal at 4 am. Found the same day at 1 pm. Presents with right MCA syndrome with severe left sided weakness. NIHSS 8.
ASPECTS 10 with hyperdense right MCA (a). CTA reveals right intracranial ICA and mid to distal M1 occlusion with good collaterals (b). Mismatch
demonstrated on CT perfusion (c). IVT not given. EVT performed and successful recanalization 13 h 29 min post last seen well time (d).
DWI confirmed right deep putamen infarct (e). Patient was discharged home on day 3 with NIHSS 0
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assessment of collaterals may help identify patients
who do not yet have established infarct and who may
still benefit from reperfusion despite unknown time of
onset [43]. Multimodal imaging has the potential to
remove strict time windows on delivering therapy, but
rather focus on individualizing therapy to patients
with salvageable brain tissue. The role of collaterals
in patient selection and outcome remains to be deter-
mined (Fig. 3).
The new trials were conducted in patients with occlu-
sion in the ICA, M1, proximal M2, A1, and proximal
A2. More distal clots were not adequately assessed in
the recent trials and occlusions of the posterior circula-
tion eg basilar artery occlusions, were not even included.
Further trials are needed to address the feasibility, effi-
cacy, and safety of extracting clots from the distal M2 or
M3 or the posterior circulation. The newer generation
retrievable stents, Solitaire and Trevo, have demon-
strated superiority in recanalization and clinical out-
comes, compared to older generation devices and
further technological developments may be geared to
reducing complications such as distal embolization.
The future is bright for acute treatment in ischemic
stroke but much work remains to be done.
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